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ABSTRACT
Keratoconjunctivitis sicca (KCS) occurs in 40%-60% of patients with chronic graft-versus-host-disease
(cGVHD) after allogeneic hematopoietic cell transplantation. Although immunosuppressive therapy is the
primary treatment of chronic GVHD, ocular symptoms require measures to improve ocular lubrication,
decrease inflammation, and maintain mucosal integrity. The liquid corneal bandage provided by a fluid-
ventilated, gas-permeable scleral lens (SL) has been effective in mitigating symptoms and resurfacing corneal
erosions in patients with KCS related to causes other than cGVHD. We report outcomes in 9 consecutive
patients referred for SL fitting for cGVHD-related severe KCS that was refractory to standard treatments. All
patients reported improvement of ocular symptoms and reduced the use of topical lubricants after SL fitting
resulting from decreased evaporation. No serious adverse events or infections attributable to the SL occurred.
The median Ocular Surface Disease Index improved from 81 (75-100) to 21 (6-52) within 2 weeks after SL
fitting, and was 12 (2-53) at the time of last contact, 1-23 months (median, 8.0) after SL fitting. Disability
related to KCS resolved in 7 patients after SL fitting. The use of SL appears to be safe and effective in patients
with severe cGVHD-related KCS refractory to conventional therapies.
© 2007 American Society for Blood and Marrow Transplantation
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iNTRODUCTION
The term keratoconjunctivitis sicca (KCS) denotes
nﬂammation caused by dryness of the conjunctiva and
ornea. Ocular chronic graft-versus-host disease
cGVHD) can cause acute conjunctival inﬂammation,
seudomembranous and cicatricial conjunctivitis, and
CS. Dry eyes or KCS occurs in approximately 40%-
0% of patients with cGVHD after allogeneic hema-
opoietic cell transplantation (HCT) [1-3] and may
epresent the only, or most signiﬁcant, clinical man-
festation and sequelae of cGVHD in some patients.
atients with KCS may develop corneal erosions
nd ﬁlaments causing severe pain and photophobia.
f inadequately managed, corneal epitheliopathy can i
016rogress to persistent epithelial defects, sterile cor-
eal ulcers, secondary infectious keratitis, and cor-
eal perforation, leading to stromal scarring and
oss of vision [4].
Systemic immunosuppressive therapy may be
eeded to halt inﬂammatory processes, and is some-
imes indicated when cGVHD of the eye is resistant to
ocal therapy or associated with other organ involve-
ent [5]. cGVHD can cause irreversible damage to
ebum and tear-producing cells, with sequelae result-
ng in considerable disability. For these patients, an-
illary and supportive care for the eye is directed to
mproving ocular surface lubrication and decreasing
nﬂammation. Such treatments include artiﬁcial tears,
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Chronic Graft-versus-Host Disease of the Eyes 1017ong-acting ocular lubricants, punctal occlusion or
auterization, ophthalmic cyclosporine [6], topical
orticosteroids, autologous serum eye drops [7], mois-
ure chamber eyewear [8], and oral administration of
holinergic agents [2-5].
Supportive care for patients with severe cGVHD
f the eye can improve the quality of life of afﬂicted
ndividuals. The liquid corneal bandage provided by a
uid-ventilated, gas-permeable scleral lens (SL) has
een effective in mitigating symptoms and resurfacing
orneal erosions in the treatment of KCS because of
ther disorders [9,10]. We therefore analyzed our
xperience on the use of SL in individuals with
GVHD-related severe KCS refractory to other ther-
pies. We report outcomes in 9 consecutive patients
eferred for SL ﬁtting as treatment for cGVHD-
elated severe KCS that was refractory to standard
herapies.
ATIENTS AND METHODS
Between April 2004 and July 2006, 9 patients were
tted with SL for refractory KCS because of cGVHD
ollowing allogeneic HCT at the Fred Hutchinson
ancer Research Center or the City of Hope. A ret-
ospective analysis was performed in November 2006
o describe the outcome of these 9 consecutive pa-
ients referred to the Boston Foundation for Sight, a
onproﬁt organization. In all cases, the decision to
reat patients by ﬁtting SL was prompted by debili-
ating ocular discomfort, visual impairment, or kera-
opathy despite systemic and local therapies as well as
ther supportive care. The status of cGVHD before
ens placement was determined by patient interviews and
retrospective review of patient records. The involve-
ent of other organs by cGVHD at any time before lens
lacement and at the time of lens placement was re-
orded, as was the duration of eye cGVHD prior to
tting the SL. Records were reviewed for prior topical
herapy for dry eyes, including the use of artiﬁcial
ears, cellulose ophthalmic inserts (Lacriserts), cyclo-
porine eye drops, doxycycline eye drops, punctal
lugs, autologous serum tears, and moisture chamber
ye wear. Data was also gathered regarding the use of
ystemic immunosuppressive treatments and cGVHD
anifestations before and at the time of SL ﬁtting and
t the time of last contact.
Fitting of SL was performed by the Boston Foun-
ation for Sight as previously described [9,10]. The
L, known as the Boston Scleral Lens, is lathed from
special polymer with an oxygen permeability value of
28  1011 cm2 mL O2/second mL mmHg and a
enter thickness ranging from 0.25 to 0.39 mm8. In
ustomization, the curvature of the central back sur-
ace of each lens is designed to maintain shallow but
eﬁnite clearance of the cornea and limbus after the pens settles, so that it is supported entirely by the sclera
nd not touching the cornea. The optimal lens vault
nd perimeter of the individual lenses are determined
y on-eye evaluations of diagnostic lenses and other
easurements.
The response to the SL was assessed by use of the
cular Surface Disease Index (OSDI). The OSDI is a
2-item questionnaire based on 3 subscales: vision-
elated function, ocular symptoms, and environmental
riggers (Table 1). Answers to questions are graded on
scale of 0 to 4, where 0 indicates none of the time, 1
ndicates some of the time, 2 indicates half of the time,
indicates most of the time, and 4 indicates all of the
ime. The OSDI has been validated as a reliable in-
trument used to assess severity of dry eye symptoms
nd vision-related function on a 0-100 scale, with
igher scores correlating with increasing symptom
everity and vision-related disability [11]. From a set
f 12 questions (Table 1) administered, a score is
alculated according to the formula: OSDI  [(sum
f scores for all questions answered)  25]/[total
umber of questions answered] [11]. From this
core, the severity of ocular surface disease is de-
ived according to a color scale, as depicted in
igure 1. In addition, questionnaires were adminis-
ered retrospectively to inquire about symptoms and
he use of artiﬁcial tears, punctal plug placement,
se of moisture chamber eyewear, and disability
ecause of eyes symptoms before and after SL
able 1. Ocular Surface Disease Index© Questionnaire
ave you experienced any of the following during the last week?
1. Eyes that are sensitive to light?
2. Eyes that feel gritty?
3. Painful or sore eyes?
4. Blurred vision?
5. Poor vision?
ave problems with your eyes limited you in performing any of
the following during the last week?
6. Reading?
7. Driving at night?
8. Working with a computer or bank machine (ATM)?
9. Watching TV?
ave your eyes felt uncomfortable in any of the following
situations during the last week?
10. Windy conditions?
11. Places or areas with low humidity (very dry)?
12. Areas that are air conditioned?
nswers to questions are graded on a scale of 0 to 4, where 0
indicates none of the time; 1, some of the time; 2, half of the
time; 3, most of the time; and 4, all of the time. The subtotal
scores for answers 1 to 5 (A), answers 6 to 9 (B), and answers 10
to 12 (C) are added together (A  B  C) to obtain D (sum of
scores for all questions answered). (E) is the total number of
questions answered (excluding questions answered N/A).
eproduced with permission from Allergan®.lacement and, at the time of last contact.
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K. Takahide et al.1018ESULTS
Patient demographics are summarized in Table 2.
iagnoses at time of HCT were acute or chronic
eukemia (n  5), myelodysplastic syndrome (n  2),
plastic anemia (n 1) and multiple myeloma (n 1).
edian patient age at the time of SL ﬁtting was 56
range: 25-64) years. All patients had prior cGVHD
nvolving multiple sites that required systematic im-
unosuppressive therapy including corticosteroids
nd cyclosporine. Four patients were receiving corti-
osteroids and 3 patients were receiving cyclosporine
t the time of SL ﬁtting. Two patients had also re-
eived treatment with azathioprine, 6 patients re-
eived mycophenolate mofetil, and 2 patients had
een treated with PUVA therapy before SL ﬁtting
Table 2). The most common cGVHD sites other
han eyes at the time of SL ﬁtting were 6 mucosal
urfaces (oral and vagina), liver (n  3), skin (n  2),
ollowed by gut (n  1) and lungs (n  1). At the time
f SL ﬁtting, 7 patients were receiving systemic im-
unosuppressive medications and 2 patients had dis-
ontinued administration of all systemic immunosup-
ressive medications after nonocular manifestations of
GVHD had resolved. Three patients had no active
anifestation of cGVHD other than KCS at the time
f SL ﬁtting.
Table 3 presents patient-reported outcomes. The
se of the SL led to improvement in ocular symptoms
n all cases. No serious adverse events or infections
ttributable to the SL occurred. All 9 patients used
opical lubricants frequently during the day before
tting the SL (baseline). In all patients, the frequency
f topical lubricant use was reduced after SL ﬁtting to
wice daily or less (n  3), 2 to 6 times daily (n  4),
r by a 50% reduction from baseline (n  2). Pre-
igure 1. The OSDI scoring system. Using the sum of scores for all
uestions answered (D) and the number of questions answered (E),
he corresponding score for the patient is then derived from the
hart. The OSDI chart has a color scheme for computation of the
everity of ocular surface disability. Reproduced with permission
rom Allergan®.cription moisture chamber eye wear was needed in 3 vatients before SL and no longer required in 2 of the
atients at last contact. All 9 patients subjectively as-
essed themselves to have disability before ﬁtting the
L, and 6 patients were no longer disabled after lens
lacement. One patient had signiﬁcant difﬁculty in-
erting the SL, even with assistance (Patient 3).
The response to the SL was assessed by patient-
eported ocular disability, use of ancillary eye care,
nd by use of the OSDI. As seen in Table 3, the
edian OSDI available improved from 81 (75-100) to
1 (6-52) within 2 weeks of SL ﬁtting and was 12
2-53) at the time of last contact, 1-23 months (me-
ian, 8.0) after SL ﬁtting.
In Patient 1, SL ﬁtting coincided with reinstitu-
ion of systemic immunosuppressive treatment, and
GVHD subsequently improved at other sites. Al-
hough the OSDI decreased promptly after SL ﬁtting,
ystemic treatment could have contributed to the res-
lution of eye symptoms. Patient 2, who had healing
f a persistent corneal epithelial defect after SL ﬁtting
Figure 2), resumed therapy with prednisone and ta-
rolimus for management of other manifestations of
GVHD at 9 months after SL ﬁtting. Patient 3 was
he only patient among the 9 who had signiﬁcant
ifﬁculty inserting the SL, even with assistance. This
atient had signiﬁcant initial improvement with reg-
lar use of the SL, but at present wears the SL only
wice monthly for no more than 4 hours because
ucous debris accumulates on the outside surface of
he lens and interferes with vision during longer periods
f use. Patients 4, 5 and 8 had signiﬁcant improvement
n ocular symptoms and also reported a signiﬁcant re-
uction in the use of topical lubricants to once or twice
aily after SL ﬁtting. Patients 6 and 7 had debris collec-
ion on the lenses that has required removal and cleaning
-2 times a day. Patient 9, despite improvement in ocular
ymptoms, remained disabled with impairment in his
bility to read and drive at night.
ISCUSSION
Our results document the response of chronic
cular GVHD-associated KCS to SL ﬁtting. KCS is
ften accompanied by cGVHD activity in other or-
ans, but may also represent the only manifestation of
GVHD [1]. The myriad and debilitating symptoms
f KCS include burning, irritation, pain, foreign body
ensation, blurred vision, and photophobia. Treat-
ent measures that can control KCS or mitigate its
ymptoms are therefore important in restoring the
uality of life of individuals after HCT.
Supportive care for the treatment of cGVHD of
he eye has been recently summarized in the National
nstitutes of Health Consensus Development Project
n Criteria for Clinical Trials in Chronic Graft-
ersus-Host Disease [4], and involves lubrication, con-
Table 2. Patient Demographics
Cases
Characteristics 1 2 3 4 5 6 7 8 9
Diagnosis Aplastic Anemia CML—CP CML—BC MDS/RA CMML CML—BC CLL MM AML
Age at SL fitting (years) 39 25 56 64 56 43 59 52 58
Chronic GVHD
Initial onset after HCT
(months)
3 7 7 12 7 26 12 2 6
Involved organs other than
eyes
Skin, liver,
mouth, gut
Skin, liver,
mouth
Skin, liver,
mouth, vagina
Skin, liver, lung,
gut, mouth
Skin, liver, lung Skin, gut mouth Mouth, joints,
vagina
Skin,
mouth
Skin,
mouth
Total duration (months) 208 20 38 110 156 46 42 69 36
Total Duration of eye
cGVHD (months)
206 20 34 110 155 28 42 69 36
Duration of eye cGVHD
before SL fitting (months)
192 7 10 92 147 25 36 63 36
Involved Organs at time of
SL fitting
Liver, mouth, GI
tract
None Skin, liver,
mouth, vagina
None None Skin, eyes Mouth, eyes Mouth,
eyes
Eyes, lungs
Prior Therapies for cGVHD PDN, CSP, TAC,
PUVA, AZA
PDN, CSP, TAC,
MMF
PDN, CSP, TAC,
MMF
PDN, CSP,
MMF
PDN, CSP, TAC,
AZA, PUVA
PDN, CSP, MMF PDN, CSP,
MMF
PDN, CSP,
TAC
PDN, CSP,
MMF
Prior Topical therapy for dry
eyes
Artificial Tears (AT) Yes Yes Yes Yes Yes Yes Yes Yes Yes
Slow release AT (Lacriserts) No Yes Yes No No No No No No
Cyclosporine eye drops Yes Yes Yes Yes No Yes Yes Yes Yes
Corticosteroids No No No No Yes No No No Yes
Punctal plugs Yes Yes Yes Yes Yes Yes Yes Yes Yes
Autologous serum tears Yes No No No No No No No No
Moisture chamber eye wear Yes No Yes Yes No No No No No
Systemic immunosuppressive
treatment at time of SL
fitting
PDN, TAC None PDN, MMF None PDN PDN, CSP, MMF,
RAPA
CSP TAC CSP, MMF
CML indicates chronic myelogenous leukemia; CP, chronic phase; BC, blast crisis; MDS, myelodysplastic syndrome; RA, refractory anemia; CMML, chronic myelomonocytic leukemia; CLL, chronic
lymphocytic leukemia; MM, multiple myeloma; AML, acute myelogenous leukemia; SL, scleral lens; PDN, prednisolone; CSP, cyclosporine; TAC, tacrolimus; AZA, azathioprine; MMF,
mycophenolate mofetil; cGVHD, chronic graft-versus-host disease; GI, gastrointestinal.
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K. Takahide et al.1020rol of evaporation, control of drainage, and decreas-
ng ocular surface inﬂammation. Ocular lubrication in
evere KCS may be achieved by the use of artiﬁcial
ears, viscous ointment, muscarinic receptor agonists,
nd cellulose ophthalmic inserts. Measures to control
vaporation include the use of moisture chamber eye
ear, tarsorrhaphy, and the use of lid care and warm
ompresses to maximize output of the meibomian
igure 2. Scleral picture before and after SL insertion. Green
uorescein dye is used to delineate punctate keratopathy, corneal
brasions, and ulcerations. a, The cornea of patient 2 before initial
ens insertion. The photograph shown in b was taken after wearing
able 3. Ocular Response to Scleral Lens (SL) Fitting
Characteristics 1 2 3
cular Surface Disease Index*
Before fitting SL 100 88 75
First 2 weeks after fitting SL 21 50 41
At last contact 8 25 53
se of prescription-type
moisture chamber eye
wear
Before fitting SL Yes No Yes
First 2 weeks after fitting SL No No Yes
At last contact No No Yes
ubjective assessment of
disability
Before fitting SL Yes Yes Yes
First 2 weeks after fitting SL No No Yes
At last contact No No Yes
ystemic Immunosuppressive
medications at last contact None PDN, TAC Unchanged
ast contact after SL fitting
(months) 14 13 23
Scoring system shown in Figure 1.che lens for 6 hours and immediately after lens removal.lands that produce the outer oil layer of the tear ﬁlm.
unctal occlusion using silicone plugs or thermal cau-
erization may be necessary to minimize ﬂuid loss
hrough drainage. Ocular surface inﬂammation may
e reduced during systemic immunosuppressive treat-
ent, judicious use of topical steroids, cyclosporine
ye drops, autologous serum eye drops, and, interest-
ngly, the ingestion of ﬂaxseed oil. In very severe cases,
ransplantation of autologous limbal epithelial cells
ay provide beneﬁt [12]. The use of SL helps to
ontrol evaporation by acting as a gas-permeable pro-
ective covering for the cornea and conjunctivae. This
rotection against evaporation and the mechanical
rauma of the eyelids allows corneal defects to regen-
rate in the presence of adequate gaseous perfusion.
All patients ﬁtted with SL for severe KCS because
f cGVHD reported a signiﬁcant reduction in topical
ubricant use compared to baseline, most likely as a
esult of decreased evaporation and the protective
herapeutic environment provided by the SL. Also
emarkable was corneal healing noticed as early as 6
ours after SL placement in some of the cases. Both
ymptomatic and clinically visible improvement was
een in all patients.
Quantiﬁable indices, use of OSDI scores, a vali-
ated tool for patient self-reporting of dry eyes [8],
lso showed consistent improvement, although retro-
pective use of OSDI may limit the validity of this
easure in our study. Nonetheless, patients can report
ccurately symptoms they experienced before SL
ear, because they experience the same symptoms if
hey leave out the SL for several days. OSDI could be
sed in prospective studies of patients with KCS
Cases
5 6 7 8 9
92 81 81 75 77
6 6 21 23 52
4 6 21 2 52
No No No No No
No No No No No
No No No No No
Yes Yes Yes Yes Yes
Yes No No No Yes
Yes No No No Yes
Unchanged Unchanged Unchanged Unchanged Unchanged
8 4 4 4 44
79
12
12
Yes
No
No
Yes
No
No
None
18aused by cGVHD. In addition, a baseline assessment
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Chronic Graft-versus-Host Disease of the Eyes 1021f ocular surface disease, which was unavailable in our
eries, represents an objective measure of KCS sever-
ty that could be used in future prospective studies of
cular GVHD.
At the present time, ﬁtting of the ﬂuid-ventilated
as-permeable SL is available only at the Boston
oundation for Sight, a nonproﬁt organization. The
rocess of custom-ﬁtting this device is costly and
ime-consuming, making its use limited to patients
ho are severely disabled by eye symptoms that have
ot responded to other treatments. Furthermore, cor-
eal endothelial dysfunction, if present, can provoke
orneal edema. Hence, the use of the device is con-
raindicated in the presence of prior corneal edema
nd, in the absence of visible edema, an evaluation of
esponse to temporary placement of a diagnostic gas-
ermeable SL is necessary. Also, some patients with
onsiderable build up of eye debris may experience
ifﬁculty with extended use of the SL.
In this study, SL placement allowed for improve-
ents in the quality of life and resumption of normal
ife activities in nearly all individuals suffering from
ebilitating cGVHD of the eye. We conclude that SL
an be a safe and effective treatment for patients suf-
ering from severe cGVHD-related KCS that is re-
ractory to other therapies. Improved accessibility of
L device would be necessary to offer this therapy to
ore patients in need.
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